Physician profile
Herbert Fechter
NPI 1063467454
$4,572.97
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $339 · 2021: $587 · 2022: $1,138 · 2023: $528 · 2024: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,012.67 | 2019-2024 | Idose, Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System |
| Alcon Vision LLC | $733.56 | 2019-2024 | Clareon, Rocklatan |
| Allergan, INC. | $536.92 | 2019-2022 | |
| New World Medical,INC. | $501.07 | 2019-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Novartis Pharmaceuticals Corporation | $178.78 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $173.41 | 2019-2024 | |
| Harrow Eye, LLC | $127.57 | 2024 | Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $122.52 | 2022-2023 | Tecnis Iol, Tecnis Simplicity |
| Eyevance Pharmaceuticals LLC | $118.18 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $115.20 | 2019 | |
| Hoffmann-La Roche Limited | $111.78 | 2019 | |
| Genentech, INC. | $104.72 | 2022 | |
| Abbvie INC. | $101.91 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $90.53 | 2023-2024 | Xiidra, Vyzulta, Envista Mx60 Iol |
| Kala Pharmaceuticals, INC. | $77.64 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $75.32 | 2019-2022 | |
| Iridex Corporation | $63.48 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $51.87 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $43.42 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $37.54 | 2021-2024 | Oxervate |
| Ocular Therapeutix, INC. | $36.38 | 2019 | |
| Nova Eye, INC. | $33.22 | 2024 | |
| Mallinckrodt Hospital Products INC. | $28.35 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.13 | 2020-2021 | |
| Amgen INC. | $20.61 | 2024 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $18.18 | 2023 | |
| Biotissue Holdings INC. | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Fechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.